

Technical Data Sheet

InVivoSIM anti-human EGFR x MET (Amivantamab Biosimilar)



Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at <https://bioxcell.com/terms-and-conditions>.

Lot Specific Information

Lot Number: Lot Specific*
Volume: Lot Specific*
Concentration: Lot Specific* (generally 4 to 11 mg/ml) *
Total Protein: Lot Specific*

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:	SIM0081
Clone:	Amivantamab
Isotype:	Human IgG1, κ
Recommended Dilution Buffer:	InVivoPure pH 7.0 Dilution Buffer
Reported Applications:	<i>in vivo</i> functional assays <i>in vitro</i> functional assays
Formulation:	PBS, pH 7.0 Contains no stabilizers or preservatives
Endotoxin:	<0.5EU/mg (<0.0005EU/ μ g) Determined by LAL gel clotting assay
Purity:	>95% Determined by SDS-PAGE
Sterility:	0.2 μ m filtration
Production:	Purified from cell culture supernatant in an animal-free facility
Purification:	Protein A
Aggregation:	<5% Determined by SEC
RRID:	
Molecular Weight:	150 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

This biosimilar antibody uses the same variable regions as the therapeutic antibody Amivantamab, making it ideal for research use. Amivantamab is a fully human IgG1 bispecific monoclonal antibody that simultaneously targets the epidermal growth factor receptor (EGFR) and c-Met (MET). By binding to these receptors, it blocks ligand binding and promotes receptor internalization and degradation. Clinically, Amivantamab is approved for the treatment of adults with non-small-cell lung cancer (NSCLC) bearing EGFR exon 20 insertion mutations, especially following disease progression after platinum-based chemotherapy. This Amivantamab biosimilar is intended only for research use, and is well suited for studying mechanisms of receptor blockade, receptor downmodulation, and immune effector activation in EGFR- and MET-driven tumor models.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at <https://bioxcell.com/faqs>.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit https://bioxcell.com/sim0081?bxcs=9k1b3a#tab_references or scan the QR code below.



Bio X Cell, LLC

<https://bioxcell.com>

+1-866-787-3444

customerservice@bioxcell.com

Conditions: For research use only. Not for human use. Not for use in diagnostic or therapeutic procedures.

Not for resale.

Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC